Drug Trial Radar · NCT05708235
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
976
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- MedSIRAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open-label, non-comparative, phase II, biomarker-driven adjuvant treatment study involving the periodic collection and analysis of blood samples from patients with HR-positive/HER2-negative early-stage BC at higher risk of relapse, who have undergone surgery within the previous five years, with no evidence of locoregional, contralateral, or distant disease. The study design is composed by an initial pre-screening phase, a molecular follow-up phase (ctDNA surveillance phase), and an interventional therapeutic phase (treatment phase). After informed consent is obtained, a total of 976 eligible patients will enter a ctDNA surveillance in which primary tumor tissue and matched normal blood will be collected from each patient to obtain a patient-specific somatic mutations panel (tumor signature). At the event of ctDNA positivity, patients will be screened to enter the treatment phase of the study. Upon confirmed eligibility, a total of 40 patients will be allocated in one of the following trial's arms adopting a sequential recruitment strategy: Arm A: Control Arm (N=10) Arm B: Experimental Arm with giredestrant (N=10) Arm C: Experimental Arm with giredestrant + abemaciclib (N=10) Arm D: Experimental Arm with giredestrant + inavolisib (N=10) If the strategy of ctDNA monitoring enables physicians to identify patients at high risk of relapse and assess whether treatment at molecular relapse can improve outcome, new cohorts may be added to the study.
Conditions
- Breast Cancer
Interventions
GiredestrantDrug
Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
AbemaciclibDrug
Abemaciclib is an orally administered CDK4/6 inhibitor
InavolisibDrug
Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
Standard ET followed by change in treatmentDrug
90-day period of standard ET in accordance with standard clinical practice, followed by one of the other three predefined treatments (giredestrant, giredestrant plus abemaciclib or giredestrant plus inavolisib if a detectable PIK3CA mutation is present and the participant also meets all additional eligibility criteria for Arm D).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of decrease or clearance in baseline ctDNA at three months after initiation of study treatmentTime frame: Treatment phase (three months after Study treatment initiation)
Locations
41 sites in 2 countries. Site status is shown where the registry gives one.
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
Hospital General Universitario Dr. Balmis
Alicante, Spain
Hospital Marina Salud de Denia
Alicante, Spain
Hospital Virgen de los Lirios
Alicante, Spain
Fundació Althaia
Barcelona, Spain
Hospital Clínic i Provincial de Barcelona
Barcelona, Spain
Hospital Universitari Dexeus
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Hospital Provincial de Castellón
Castellon, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital del Vinalopó
Elche, Spain
Institut Català d' Oncologia Girona (ICO)
Girona, Spain
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
Complejo Hospitalario de Jaén
Jaén, Spain
Hospital Universitario de León
León, Spain
Hospital Universitario Arnau de Vilanova de Lleida
Lleida, Spain
Clínica Universidad de Navarra
Madrid, Spain
Hospital Beata María Ana
Madrid, Spain
Hospital Universitario de Torrejón
Madrid, Spain
Hospital Universitario Doce de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Sanchinarro-START-CIOCC
Madrid, Spain
Hospital Regional Universitario de Málaga (Hospital Carlos Haya)
Málaga, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Hospitalario Universitario de Navarra
Pamplona, Spain
Hospital de Sagunto
Sagunto, Spain
Hospital Quirónsalud Sagrado Corazón
Seville, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Hospital Universitari Sant Joan de Reus
Tarragona, Spain
Hospital Arnau de Vilanova de Valencia
Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politècnic La Fe
Valencia, Spain
Hospital Universitario La Ribera, Alzira
Valencia, Spain
Complejo Hospitalario Universitario de Vigo
Vigo, Spain
Hospital de Xativa
Xàtiva, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
University Hospital Coventry
Coventry, United Kingdom
Royal Surrey County Hospital NHS Foundation Trust
Guildford, United Kingdom
Barts Cancer Institute
London, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.